Tag: Exact Sciences
-
Abbott completes acquisition of Exact Sciences
ABBOTT PARK, Ill., March 23, 2026 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has completed the acquisition of Exact Sciences, establishing Abbott as a leader in fast-growing cancer screening and diagnostics segments and enabling the company to serve millions of additional people. “Abbott’s global scale, track record of operational and commercial excellence and work with healthcare…
-
Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
ABBOTT PARK, Ill., and MADISON, Wis., Nov. 20, 2025 /PRNewswire/ — Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people. Under the terms of the agreement, Exact Sciences shareholders will receive $105 per…
-
Exact Sciences Launches the Cologuard™ Plus Test, Transforming Colorectal Cancer Screening
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date Madison, Wis., March 31, 2025 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Cologuard Plus™, the…
-
New Evidence Validates ONCODETECT’S™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients
Results from prospective molecular residual disease (MRD) study show a positive Oncodetect test result is strongly associated with recurrence in stage III colon cancer patients Oncodetect test achieved the primary endpoint in a second clinical validation study, extending its prognostic value into stages II and IV colon cancer and rectal cancer Exact Sciences plans to launch the Oncodetect test in Q2 2025 with Medicare coverage Key collaborations support clinical evidence…
-
Exact Sciences and PGA Tour Champions extend long-running partnership in Tucson
Tucson, Ariz. (February 1, 2023) – The PGA TOUR Champions, the Tucson Conquistadores, the First Tee Tucson, and Exact Sciences, the maker of Cologuard®, announced today that the Madison, Wisconsin-based company will now be the presenting sponsor of the Cologuard Classic. The announcement also extends Cologuard’s title sponsorship through the 2027 season. The 2023 Cologuard Classic…
-
Meet Exact Sciences: The PBC company behind Cologuard
Exact Sciences joined the Phoenix Bioscience Core when it acquired a pair of Phoenix-based startups from the Translational Genomics Research Institute (TGen) and the International Genomics Consortium. The Wisconsin-based company is most well known for its at-home colorectal screening product, Cologuard. Exact Sciences Vice President of Precision Oncology Business Operations Kevin Parker sat down with…
-
Exact Sciences awards grants to health centers focused on improving cancer screenings in vulnerable populations
Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today awarded $525,000 in grants to eight federally qualified health centers focused on improving colorectal cancer screening rates in vulnerable populations, including Mountain Park Health Center in Phoenix.
-
Exact Sciences presents new data on biomarkers in the blood that can signal for cancer
Exact Sciences recently presented new data from a multi-cancer early detection biomarker validation study that showed the performance of four biomarkers found in the blood that can signal the presence of cancer in the body.
